沙库巴曲缬沙坦对心肌梗死后心力衰竭患者的临床疗效

Comparison of effects of sacubitril/valsartan versus valsartan on post-AMI heart failure

目的探讨沙库巴曲缬沙坦治疗心肌梗死后心力衰竭的临床效果。方法选取空军军医大学附属西京医院2018年6月~2019年6月心梗后心力衰竭的患者146例为研究对象,在常规治疗的基础上,随机将其分为两组:缬沙坦组(对照组,n=71)和沙库巴曲缬沙坦组(试药组,n=75),随访1年检测患者心脏彩超,血肌酐,血尿素氮,氨基末端脑钠尿肽前体(NT-proBNP)及生活质量相关指标。结果①治疗1个月,试药组患者较对照组NT-proBNP显著下降(P<0.05),6分钟步行距离,明尼苏达生活质量评分显著升高(P<0.05),纽约心功能分级分布显著改善(P<0.05);②治疗1年后,试药组患者左室射血分数(LVEF),左室收缩末期容积(LVESV)较对照组显著改善(P<0.01),NT-proBNP及生活质量相关指标进一步改善(P<0.05)结论沙库巴曲缬沙坦较缬沙坦对心梗后心力衰竭患者心功能和生活质量有更好的疗效。

AIM To explore the therapeutic effects of sacubitril/valsartan versus valsartan on cardiac functions and qualities of life in post-acute myocardial infarction(AMI) heart failure patients.METHODS From July 2018 to July 2019,146 post-AMI heart failure patients were selected and randomly divided into valsartan group(n = 71) and sacubitril/valsartan group(n = 75).The patients were followed up for 1 year and their chocardiography,serum creatinine,blood urea nitrogen,NT-proBNP and quality of life-related parameters were collected at 1 month and 1 year.RESULTS After 1 month treatment,the improvements of NT-proBNP,6 minutes’ walking distance,NYHY classification and MLHFQ scale in sacubitril/valsartan group were significantly larger than those in valsartan group(P <0.05).After 1 year treatment,the improvements of LVEF and ESV in sacubitril/valsartan group were also significantly larger than those in valsartan group(P<0.01).And so were the improvements in NTproBNP,6 minutes’ walking distance,NYHY classification and MLHFQ scale(P<0.05).CONCLUSION Post-AMI patients benefit more from sacubitril/valsartan than valsartan for their cardiac functions and qualities of life.